| Company Name | Pfizer Inc. |
|---|---|
| Protocol Number | A4061076 |
| Title of Study | Post-Marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice |
| Primary Objective | The primary objective of this registry is to monitor the dose adjustment of INLYTA® in real world routine practice. The secondary objectives include safety profile, objective response rate, and progression-free rate in real world routine practice. |
| Number of Sites | 6 |
| Period of Study | From：Dec. 1, 2015 to：Dec. 31, 2017 |
| Number of Patients | NA, Given this is a registry rather than a clinical research of comparison, the sample size is limited by actual patients fulfill the inclusion criteria and without any situation listed in exclusion criteria treated in Taiwan during the registry period; a calculated sample number is not applicable for present setting.人 |
| IRB Approval Date | Nov. 3, 2015 |
| Publication Plan / Date | Dec. 31, 2018 |
